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Statement of translational relevance 
The anti-EGFR monoclonal antibody cetuximab is effective for the treatment of patients 
with ‘RAS’ wild-type metastatic colorectal cancer (mCRC). Unfortunately, responses are 
transient and most patients develop acquired resistance. In the present study, we 
analysed the genetic profile of clinical specimens and preclinical models of acquired 
resistance to cetuximab, revealing a complex pattern of mutations in both EGFR and its 
downstream effectors, KRAS, NRAS, BRAF and PIK3CA. We discovered five novel point 
mutations in the ectodomain of EGFR, which confer resistance to cetuximab. Of note, only 
a subset of these EGFR variants remains sensitive to panitumumab. Accordingly, 
identification patient-specific mechanisms of resistance to EGFR blockade will be 
paramount to design additional lines of therapy.  
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Abstract 
Purpose: Colorectal cancer (CRC) patients who respond to the anti-EGFR antibody 
cetuximab often develop resistance within several months of initiating therapy. To design 
new lines of treatment the molecular landscape of resistant tumors must be ascertained. 
We investigated the role of mutations in the EGFR signalling axis on the acquisition of 
resistance to cetuximab in patients and cellular models. 
Experimental Design: Tissue samples were obtained from 37 CRC patients who became 
refractory to cetuximab. CRC cells sensitive to cetuximab were treated until resistant 
derivatives emerged. Mutational profiling of biopsies and cell lines was performed. 
Structural modeling and functional analyses were performed to causally associate the 
alleles to resistance. 
Results: The genetic profile of tumor specimens obtained after cetuximab treatment 
revealed the emergence of a complex pattern of mutations in EGFR, KRAS, NRAS, BRAF 
and PIK3CA genes, including two novel EGFR ectodomain mutations (R451C and K467T). 
Mutational profiling of cetuximab resistant cells recapitulated the molecular landscape 
observed in clinical samples and revealed three additional EGFR alleles: S464L, G465R 
and I491M. Structurally, these mutations are located in the cetuximab-binding region, 
except for the R451C mutant. Functionally, EGFR ectodomain mutations prevent binding 
to cetuximab but a subset is permissive for interaction with panitumumab.  
Conclusion: Colorectal tumors evade EGFR blockade by constitutive activation of 
downstream signalling effectors and through mutations affecting receptor-antibody binding. 
Both mechanisms of resistance may occur concomitantly. Our data have implications for 
designing additional lines of therapy for CRC patients who relapse upon treatment with 
anti-EGFR antibodies. 
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Introduction 
Monoclonal antibodies (moAbs) directed against the epidermal growth factor receptor 
(EGFR) --cetuximab and panitumumab-- provide significant survival benefit to patients with 
RAS wild-type metastatic colorectal cancer (mCRC) and are now standard components of 
treatment regimens for these patients, either alone or in combination with chemotherapy. 
However, the duration of this response is only transient and does not last more than 3 to 
12 months, after which secondary resistance occurs (1-5). Definition of the molecular 
changes underlying acquired resistance to anti-EGFR antibodies is needed to improve 
clinical benefit and devise further lines of treatment. Molecular profiling of patient samples 
and preclinical models have previously defined a number of mechanisms of secondary 
resistance. The most common event is the emergence of KRAS and NRAS mutations 
which occurs in approximately 50-80% of the cases (6-10). Other escape routes include 
acquisition of the S492R mutation in the ectodomain of EGFR (10-13), as well as 
amplification of tyrosine kinase receptor genes HER2 or MET (14, 15). Interestingly, recent 
data indicate co-existence of several molecular mechanisms of secondary resistance 
within an individual patient (6-10, 12, 16).  
 
To identify yet unknown molecular events leading to anti-EGFR treatment failure, we 
investigated the role of mutations in the EGFR signaling pathway on the acquisition of 
resistance to cetuximab in CRC patients and cellular models. Our findings suggest that we 
have yet to fully characterize the complete spectrum of genetic variants through which 
colorectal tumors evade EGFR blockade. The data presented here will help design 
additional therapeutic strategies to circumvent resistance of CRC patients who receive 
EGFR targeted antibodies. 
 
 
Materials and Methods 
 
Tumor samples and patients 
All mCRC consenting patients treated with anti-EGFR moAb at Hospital del Mar between 
January 2010 and June 2013 were included in this study. In the analysis, we only included 
patients who had good quality paired pre- and post- treatment biopsies and who acquired 
resistance to anti-EGFR based-therapy defined as progression disease following a) 
complete response or partial response or b) stable disease for more than 16 weeks. 
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Response was evaluated according to the Response Evaluation Criteria in Solid Tumors 
(RECIST) (17). Our study included re-biopsy following treatment failure in patients who 
consented to this extra procedure. Re-biopsies at the time of progression were obtained 
from the most accessible lesion with less potential risk of related complications for the 
patient according to ethical considerations. Pre-treatment sample was obtained from the 
regular diagnosis procedure. In this study, we included nine cases (patients #21 to #28 
and patient #36) that had been previously assessed for EGFR S492R, KRAS exon 2, 
BRAF V600E and PIK3CA mutations by Sanger sequencing (12) and that in the current 
work were analyzed for a broader panel of mutations as specified below using more 
sensitive sequencing technologies. Biological samples were obtained from Parc de Salut 
Mar Biobank (MARBiobanc). This study was approved by the local Ethics Board (CEIC-
2012/4741/I). All participating patients signed written informed consent. 
 
Mutational analysis in tissue samples 
DNA extraction from tumoral samples was performed as previously described (12). 
Mutational analysis of KRAS (exons 2, 3 and 4), BRAF (exon15), NRAS (exons 2 and 3), 
PIK3CA (exons 9 and 20) and EGFR (exon 12) was performed by Sanger sequencing 
using BigDye v3.1 (Applied Biosystems, Foster City, CA) following manufacturer’s 
instructions and analyzed on a 3500Dx Genetic Analyzer (Applied Biosystems). KRAS 
(exons 3 and 4) and NRAS (exons 2, 3 and 4) were also analyzed by pyrosequencing 
(Qiagen) and KRAS (exon 2) was also assessed by Therascreen real time PCR (Qiagen) 
following the manufacturer’s instructions. All cases were also screened by pyrosequencing 
using a Next Generation Sequencing (NGS) 454 GS Junior platform (Roche Applied 
Science, Mannheim, Germany). Processed and quality-filtered reads were analyzed using 
the GS Amplicon Variant Analyzer software version 2.5p1 (Roche). Mutations detected by 
NGS were confirmed by competitive allele-specific TaqMan® PCR (CAST-PCR, Applied 
Biosystems) when specific assays were available. 
 
Cell culture and generation of resistant cells 
DiFi cells were cultured in F12 medium (Invitrogen) supplemented with 5% FBS; OXCO-2 
cells were cultured in Iscove’s medium (Invitrogen) supplemented with 5% FBS; LIM1215 
cells were cultured in RPMI-1640 medium (Invitrogen) supplemented with 5% FBS and 
insulin (1 µg/ml); NCIH508 cells were cultured in RPMI-1640 medium (Invitrogen) 
supplemented with 5% FBS; HCA-46 cells were cultured in DMEM medium (Invitrogen) 
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supplemented with 5% FBS and CCK81 cells were cultured in MEM medium (Invitrogen) 
supplemented with 5% FBS. All media contained also 2mM L-glutamine, antibiotics 
(100U/mL penicillin and 100 mg/mL streptomycin) and cells were grown in a 37°C and 5% 
CO2 air incubator. The DiFi and OXCO-2 cell lines were a kind gift from Dr. J. Baselga in 
November 2004 (Oncology Department of Vall d'Hebron University Hospital, Barcelona, 
Spain) and Dr V. Cerundolo in March 2010 (Weatherall Institute of Molecular Medicine, 
University of Oxford, UK), respectively. The LIM1215 parental cell line has been described 
previously (18) and was obtained from Prof. Robert Whitehead, Vanderbilt University, 
Nashville, with permission from the Ludwig Institute for Cancer Research, Zurich, 
Switzerland. The NCIH508 cell line was purchased from American Type Culture Collection 
(LGC Standards S.r.l). HCA-46 cell lines was obtained from ECACC (distributed by Sigma-
Aldrich Srl). CCK81 cell line was obtained from HSRRB, Japan. The identity of each cell 
line was tested and authenticated by Cell ID™ System and by Gene Print® 10 System 
(Promega), through Short Tandem Repeats (STR) at 10 different loci (D5S818, D13S317, 
D7S820, D16S539, D21S11, vWA, TH01, TPOX, CSF1PO and amelogenin). Amplicons 
from multiplex PCRs were separated by capillary electrophoresis (3730 DNA Analyzer, 
Applied Biosystems) and analyzed using GeneMapperID software from Life Technologies.  
Resulting cell line STR profiles were cross-compared and matched with the available STR 
from ATC, ECCAC, and CellBank Australia repositories online databases. All cell lines 
were tested and resulted negative for mycoplasma contamination with Venor® GeM 
Classic kit (Minerva biolabs). 
Generation of resistant cells utilized in this manuscript has already been previously 
described (6, 9). CCK81 cetuximab-resistant derivatives were obtained by increasing the 
cetuximab dosage stepwise from 680  nM to 1.4 µM during the course of six months.  
 
Mutational analysis in cell lines 
Genomic DNA samples were extracted by Wizard® SV Genomic DNA Purification System  
(Promega). For Sanger Sequencing, all samples were subjected to automated sequencing 
by ABI PRISM 3730 (Applied Biosystems). Primer sequences are listed elsewhere (6, 9). 
The following genes and exons were analyzed: KRAS (exons 2, 3 and 4), NRAS (exons 2 
and 3), PIK3CA (exons 9 and 20), BRAF (exon 15), EGFR (exon12). All mutations were 
confirmed twice, starting from independent PCR reactions. 
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Drug assays  
Cetuximab was obtained from the Pharmacy at Niguarda Ca’ Granda Hospital, Milan, Italy.  
Cell lines were seeded in 100 µL medium at the following densities (2x103  for DiFi, 1.5 
x103  for LIM1215, HCA-46, NCIH508 and OXCO-2, 3x103 for CCK81) in 96-well culture  
plates. After serial dilutions, cetuximab in serum-free medium was added to cells, and  
medium-only wells were included as controls. Plates were incubated at 37°C in 5% CO2 
for 6 days, after which cell viability was assessed by ATP content using the CellTiter-Glo® 
Luminescent Assay (Promega). 
 
DNA constructs and mutagenesis 
The pLX301-EGFR WT construct was a generous gift from Dr. C. Sun and Prof R. 
Bernards (NKI, Amsterdam). EGFR mutants containing the 6 point mutations (R451C, 
S464L, G465R, K467T, I491M and S492R) were constructed using the QuikChange® II 
site-directed mutagenesis kits from Agilent Technologies with pLX301-EGFR WT plasmid 
as the template DNA. The presence of mutations was confirmed by DNA sequencing.  
 
Droplet Digital PCR 
Isolated gDNA was amplified using ddPCR™ Supermix for Probes (Bio-Rad) using KRAS, 
NRAS, BRAF and EGFR assay (PrimePCR™ ddPCR™ Mutation Assay, Bio-Rad and 
custom designed). ddPCR was performed according to manufacturer’s protocol and the 
results reported as percentage or fractional abundance of mutant DNA alleles to total 
(mutant plus wild type) DNA alleles. 8 to 10 µl of DNA template was added to 10 µl of 
ddPCR™ Supermix for Probes (Bio-Rad) and 2 µl of the primer/probe mixture. This 20 µl 
sample was added to 70 µl of Droplet Generation Oil for Probes (Bio-Rad) and used for 
droplet generation. Droplets were then thermal cycled with the following conditions: 5 
minutes at 95°C, 40 cycles of 94°C for 30s, 55°C for 1 minute followed by 98°C for 10 
minutes (Ramp Rate 2°C/sec). Samples were then transferred to a QX200™ Droplet 
Reader (Bio-Rad) for fluorescent measurement of FAM and HEX probes. Gating was 
performed based on positive and negative controls, and mutant populations were 
identified. Fractional Abundances of the mutant DNA in the wild-type DNA background 
were calculated for each sample using QuantaSoft software (Bio-Rad). Multiple replicates 
(minimum of four) were performed for each sample. ddPCR analysis of normal control 
gDNA from cell lines and no DNA template (water) controls were performed in parallel with 
all the samples, including again multiple replicates as a contamination-free control.  
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EGFR probes and primers sequences are available upon request. 
 
Molecular Simulations 
Input coordinates for the structure of cetuximab bound to wild type sEGFR (extracellular 
part) were taken from PDB:1YY9 (19). The system was parameterized using the Amber12 
force field (20) and solvated and neutralized in a TIP3P water box. Energy minimization 
was conducted under NPT conditions at 1 atm, 298K and a cutoff of 9 Ǻ, with rigid bonds 
and PME for long-range electrostatics. Potential energy minimization was run for 2ps. 
During minimization the heavy protein atoms were not restrained. The simulation was run 
using ACEMD (21) on a local GPU-equipped workstation. 
 
Flow Cytometry 
To measure cetuximab and panitumumab binding to cells expressing mutant EGFR, we 
harvested by trypsinization and washed the cells twice with PBS. We incubated the cells 
with Fc blocking solution for 15 m on ice to block non-specific Fc binding of 
immonuglobulins. We then washed the cells and incubated them with the monoclonal 
antibodies for EGFR binding during 30 m on ice. To visualize the primary antibody a goat 
anti-human IgGγ ficoerythrin-conjugated (Invitrogen) was used as a secondary antibody. 
EGFR binding was analyzed using the FACScan flow Cytometer. 
 
Protein detection 
We subjected total cell lysates to Western blot analysis as previously reported (12). The 
phospho EGFR antibody (Y1068) was purchased from Cell Signalling Technology. 
 
Results 
 
Emergence of EGFR ectodomain mutations in patients treated with cetuximab 
Thirty-seven consecutive patients with metastatic colorectal cancer who had acquired 
resistance to cetuximab after an initial response to the treatment and had good quality 
paired pre- and post- treatment specimens were included in this study. Tumor biopsy 
obtained during the regular diagnosis procedure was used as the pre-treatment sample. In 
most cases this sample was obtained from the primary tumor during routine colonoscopy. 
Biopsies at progression were taken from liver (21 samples), lung (6), bone (2), peritoneum 
(3), colon-rectum (3), retroperitoneal lymph node (1) and subcutaneous node (1) with 
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ultrasound guidance, CT-scan guidance, or colonoscopy in the case of colon-rectum 
lesions. There were no major biopsy-related complications. Patients’ clinical characteristics 
are showed in Supplementary Table S1.  
 
All pre-treatment biopsies were screened for mutations in KRAS, NRAS and BRAF by 
Sanger and pyrosequencing as part of routine clinical practice at Hospital del Mar 
(Barcelona). Mutations in PIK3CA and EGFR were also assessed as part of this study. All 
pre-treatment biopsies were wild type except for three samples that harbored mutations in 
PIK3CA. Since PIK3CA mutations do not preclude response to anti-EGFR therapy, these 
patients were treated with cetuximab-based regimens. Post-treatment tissue samples were 
analyzed for the same mutations using the same sequencing platforms. In total, we 
detected the emergence of 31 mutations in post-treatment biopsies from 20 patients 
(Table 1). The additional 17 post treatment samples did not reveal variants in any of the 
genes we analyzed. In seven cases, mutations in different genes were detected in the 
same tissue sample (median of detected mutations within the same specimen 2, range 1-
5) (Table 1).  
 
Acquired mutations were found in NRAS (9 events) and KRAS genes (8 events) followed 
by mutations in PIK3CA (6 events) and BRAF (3 events). Interestingly, mutations in RAS 
frequently occurred in exons 3-4 (67% of NRAS and 50% of KRAS mutations). Of note, 
mutations in PIK3CA always coexisted with other mutations within the same sample. 
 
Notably, in addition to ‘RAS’ gene mutations the molecular analysis revealed the 
emergence of multiple alleles in the EGFR extracellular domain. The previously reported 
EGFR S492R variant was detected in three patients. Of note, EGFR mutations were 
accompanied by gene amplification in both the pre- and the post- treatment specimen from 
two of these patients (data not shown); in the third patient, EGFR gene copy number was 
not assessed due to lack of sufficient tissue for FISH analysis. 
 
Two novel mutations located in exon 12 of the EGFR gene were discovered by the 
analysis of post treatment samples. Patient #31 harboured an A -> C substitution at codon 
1400 that caused a substitution of a lysine to threonine at aminoacid 467 (p.K467T). The 
post-cetuximab biopsy from patient #35 harbored a C -> A substitution at codon 1351, 
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resulting in an arginine to cysteine substitution at aminoacid 451 (p.R451C) (Table 1 and 
Supplementary Fig. S1). 
 
EGFR ectodomain mutations and acquired resistance to cetuximab in CRC cell models 
We previously reported that acquisition of resistance in CRC cells is associated with 
emergence of KRAS, BRAF and NRAS activating mutations (6, 9, 12). To discover 
additional mechanisms of resistance to EGFR blockade we exploited 5 CRC cell lines 
(DiFi, LIM1215, HCA-46, NCIH508, OXCO-2 and CCK81), which are highly sensitive to 
cetuximab (Supplementary Fig. S2). These cell lines are wild type for KRAS, NRAS, BRAF 
and PIK3CA with the exception of NCIH508, which displays the p.E545K PIK3CA 
mutation. Altogether, these cell models recapitulate the molecular features of tumors from 
CRC patients likely to respond to anti EGFR therapies. For each line, at least five million 
cells were exposed continuously to cetuximab until resistant populations emerged 
(Supplementary Fig. S2). To define molecular mechanisms underlying acquisition of 
resistance, we initially performed Sanger sequencing of genes involved in regulation of the 
EGFR signalling pathway (EGFR, KRAS, BRAF, NRAS, and PIK3CA). In accordance with 
our previous reports, resistant populations often displayed KRAS, BRAF and NRAS 
mutations (Table 2) (9). All of these alleles were detected in the resistant cells but not in 
the corresponding parental population from which they originated. Importantly, in several 
occasions multiple genetic alterations were concomitantly present in the resistant cell 
population (Table 2) indicating their polyclonal status. To assess the molecular features of 
individual clones we performed limited cell dilutions of LIM1215 and CCK81 as these cell 
lines are amenable to this procedure. We then subjected single clones to Sanger 
sequencing for candidate genes (EGFR, KRAS, BRAF, NRAS, and PIK3CA). Notably, 
mutation profiling of clones identified three novel EGFR variants: S464L, G465R and 
I491M (Supplementary Fig. S3). Considering that the resistant derivatives are polyclonal, 
and in light of the limited sensitivity of the Sanger sequencing method, we postulated that 
variants present in less than 20% of the cell populations might have remained undetected. 
To identify mutations present at low frequency we employed droplet digital PCR (ddPCR) 
which is known to have a mutant/wild type sensitivity of 1:20000. ddPCR probes were 
designed and individually validated using control mutant DNA to detect EGFR variants 
previously identified in tumor biopsy or cell lines (Supplementary Table S2).  This analysis 
unveiled the presence 3 new EGFR variants (S464L, G465R, and I491M) that were not 
detected by Sanger sequencing in resistant cell populations (Table 2 and Supplementary 
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Table S3). The ddPCR approach could not be performed in tissue samples since there 
was no sufficient material available.  Overall, the mutational landscape of cell lines with 
acquired resistance to cetuximab, recapitulate the molecular profiles of tumors that 
relapsed upon cetuximab treatment.  
 
Structural model analysis of EGFR ectodomain mutations  
To understand how the EGFR ectodomain mutations detected in tumor samples and cell 
lines could drive resistance to EGFR blockade we performed computational structure-
based analyses. With the exception of R451C, the EGFR mutations are located in the 
receptor region, which has been shown to interact with cetuximab (Fig. 1A). More 
specifically, the S464L, G465R, K467T, I491M and S492R mutations lie in the middle of 
the surface recognized by the antibody (Fig. 1B) and therefore modifications of this 
interface has the potential to affect complex formation. Of these five mutations, three 
appear to disrupt favourable interactions, namely S464L, K467T, and I491M. The polar 
aminoacid S464 is within H-bond distance from the carbonyl backbone of Y102 and the 
phenolic OH-group of Y104 (Fig. 1C). Replacement by a hydrophobic bulky aminoacid as 
leucine (S464L) has the potential to disrupt the network. Analogously, the positively 
charged aminoacid K467 is involved in a stabilizing salt bridge with E58 (Fig. 1C). Insertion 
of a polar but neutral aminoacid as threonine K467T, although still permitting the H-bond 
E58, would affect the favourable electrostatic interaction. Residue I491 is a rather large, 
aliphatic residue located in a hydrophobic cavity mainly formed by aromatic aminoacids 
(Fig. 1C). Although the side chains present similar size, methionine (I491M) is a polar 
aminoacid and would be unfavourably located in a nonpolar environment. The other two 
mutations (G465R and S492R) involve the change from rather small, polar and uncharged 
side chain to a large and electrically charged side chain in arginine (Fig. 1C) (13).  
 
R451C is the only mutation not located in the cetuximab-binding site, however, the 
mutation could lead to critical structural changes. As the domain IV is formed by a 
sequence of disulphide bonds, which preserve its tertiary structure, the replacement by a 
cysteine at that position could perturb one of the disulphide bonds in domain III (C475-
C462) possibly forming a new one between domains III and IV (C451-C475). We verified 
that the distance in the crystal structure between these residues (C451-C475, carbon 
alpha distance 6.8 Å) is compatible with the formation of a disulphide bond. Indeed, a 
system setup in this new configuration successfully minimizes to a C451-C475 distance of 
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5.2 Å. Overall, all identified mutations in EGFR (except R451C) were located in the 
cetuximab binding epitope.  
 
Biochemical and functional analyses of EGFR ectodomain mutations 
To experimentally assess the impact of the EGFR ectodomain mutations on the ability of 
the receptor to interact with cetuximab we performed forward genetic experiments on a 
subset of the newly discovered mutations. Wild type and mutant EGFR cDNAs were 
ectopically expressed in NIH 3T3 cells that lack endogenous EGFR. Flow cytometry was 
used to establish the extent of cetuximab binding to cells expressing the mutants; wild type 
EGFR and S492R served as positive and negative controls respectively. These 
experiments clearly showed that the newly discovered EGFR K467T, R451C, S464L, 
G465R and I491M mutations were not permissive for binding to cetuximab thus providing 
functional evidence of their role in driving acquired resistance to EGFR blockade. Of note, 
the effect of EGFR R451C on cetuximab binding was less prominent compared to the 
other mutants (Fig. 2).  
 
To further characterize the functional properties of the EGFR mutations we performed 
biochemical studies in cells expressing individual mutations. As expected cetuximab 
abrogated ligand-mediated activation of the wild type receptor, while had no or very limited 
impact in cells carrying mutated EGFR (S464L, G465R, K467T, I491M and S492R) (Fig. 3).  
Notably, in R451C mutant cells, cetuximab was still capable of inhibiting EGFR 
phosphorylation (Fig. 3). 
 
We then examined whether panitumumab, the other anti-EGFR drug approved to treat 
CRC, was active in cells overexpressing EGFR mutations. As previously described, 
S492R mutant cells efficiently bound to panitumumab (12). We found that the K467T and 
R451C mutants were to some extent permissive for panitumumab binding, while S464L, 
G465R and I491M mutants did not bind to this antibody (Fig. 2). Accordingly, biochemical 
analyses showed that panitumumab prevents EGFR activation in S492R, K467 and 
R451C mutants (Fig. 3). 
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Discussion  
 
We present a comprehensive analysis of mutational changes affecting key members of the 
EGFR signaling pathway emerging in tumor biopsies of patients treated with cetuximab 
and in cell models, which acquired resistance to cetuximab in vitro. We found that 
colorectal cancer cells evade EGFR blockade through two main strategies. The main 
mechanism of resistance involves downstream pathway reactivation which occurs in 43% 
of patients’ samples and 58.8% of the cells respectively. The second entails EGFR 
extracellular domain mutations that were we detected in 10.8% of patients’ samples and 
29% of the cells. Although these different codons in cells and patients, our findings 
highlights a remarkable overlap among the resistant mechanism observed in preclinical 
models and patients samples (22). The cell-based findings may be translated back into the 
clinic. For example the EGFR ectodomain alleles, initially discovered in cells, might 
reasonably also be present in patients who relapse upon EGFR blockade and this could 
be verified using tissue and liquid biopsies. 
 
The molecular landscape of acquired resistance to EGFR blockade revealed the 
emergence of multiple point mutations in the ectodomain of EGFR. In particular we 
detected two novel EGFR exon 12 mutations (EGFR p.R451C and p.K467T) in two 
patients. The previously reported EGFR S492R mutation was detected in 3 out of 37 post-
cetuximab tissue samples (8%), while a recent study reports 16% of S492R EGFR 
mutation detection in 239 post-cetuximab plasma samples (11). Such differences may be 
explained by different sensitivity of the detection techniques as well as the ability of plasma 
samples to capture the heterogeneity of solid tumors as compared to single biopsies of 
one tumoral lesion (8, 16, 23). Plasma samples of the patients included in the current 
study were not systematically collected and therefore we could not analyze the prevalence 
of EGFR mutations in circulating tumor DNA in the cohort. Accordingly, studies in larger 
cohorts of patients treated with cetuximab or panitumumab are warranted to define the 
exact frequency of the other newly identified EGFR ectodomain mutations.  Of note, most 
samples harboring the EGFR S492R mutation also exhibited EGFR gene amplification 
(12), similar to lung cancer tumors harboring the T790M mutation of resistance to tyrosine-
kinase inhibitors, where the T790M allele appears to be selectively amplified (24). 
Interestingly, our in vitro analysis showed that panitumumab was effective in a subset of 
EGFR mutants. Since the binding epitopes of cetuximab and panitumumab overlap but are 
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not identical, it is foreseeable that mutations arising in EGFR after anti-EGFR treatment 
will differentially disrupt binding of cetuximab and/or panitumumab to the receptor (25), 
with relevant clinical implications for the treatment of cetuximab resistant patients.  
 
Activating mutations in EGFR downstream signaling effectors were the most frequent 
event in both cell models and patients. Emergence of KRAS and NRAS mutations 
occurred in 42% of patients, similar to what we have previously reported in tissue samples, 
but lower than previously reported in plasma samples (6-10). Again, this may be due to the 
advantage of circulating DNA in capturing the heterogeneity of solid tumors compared to 
biopsy of one tumoral lesion (8, 16, 23), indicating that diagnostic tools such as liquid 
biopsies are required to capture the complexity of the disease. As recently reported, RAS 
mutations often occurred outside of exon 2 in clinical samples and cell models (26, 27). 
The finding that codon 61 and 146 KRAS mutations occur more frequently in the acquired 
resistance setting than in the general colorectal cancer population is worth further studies. 
Of note, all samples harboring a PIK3CA mutation also displayed other mechanisms of 
resistance. The role of PIK3CA mutations in driving acquired, as well as primary, 
resistance remains controversial and needs to be further characterized. We did not identify 
emergence of molecular alterations in 20% of patients, suggesting limitations in the 
sensitivity of the detection technique, tumor heterogeneity, as well as other mechanisms of 
resistance such as ligand overexpression or c-MET amplification (15, 28, 29). 
 
Importantly, multiple mechanisms of resistance were often present in the samples from 
relapsed tumors often diplayed more than one molecular alteration. This was also 
observed in cell lines resistant to cetuximab, strongly suggesting their polyclonal status. 
This likely reflects the heterogeneity of colorectal cancers and supports the role of 
circulating DNA to comprehensively characterize the molecular landscape of resistance to 
EGFR blockade in patients. Activation of EGFR-RAS signaling axis as well as EGFR 
ectodomain mutations frequently co-occurred. These findings suggest the design of clinical 
trials that include concomitant inhibition of EGFR downstream signaling together with 
direct inhibition of the EGFR receptor. Considering that panitumumab seems to be 
ineffective on a subset of the newly discovered mutations, drugs inhibiting EGFR through 
different mechanism will also be needed.  
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Our results have implications for the care of patients as they support the necessity of re-
assessing the molecular landscape of tumors after progression to anti-EGFR drugs, which 
currently is not routinely done in clinical practice. The plasticity of tumor cells and their high 
capacity of adaptation under selective drug pressure, emphasizes the need for sequential 
tumor or plasma biopsies to better monitor and personalize treatment.  
 
In summary, our study highlights the importance of reassessing the molecular profile of the 
overall disease burden longitudinally during therapy, and provides evidence that acquired 
resistance to anti-EGFR therapy in mCRC patients arises from the emergence of 
heterogeneous and overlapping molecular changes. Such complexity converges on two 
main mechanisms of resistance: activating mutation in EGFR downstream signalling and 
mutations in EGFR ectodomain that disrupt antibody-receptor binding. In light of these 
findings, pharmacological studies combining inhibition of both EGFR and EGFR 
downstream signaling effectors to bypass cetuximab resistance are warranted. 
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Arena et al, Table 2. EGFR pathway mutations in parental and cetuximab 
resistant cell lines.  
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Table and Figure legends 
 
Table 1. EGFR pathway mutations in tissue samples from metastatic colorectal 
cancer patients treated with cetuximab. KRAS, NRAS, BRAF, PIK3CA and EGFR 
mutations were analyzed in paired tissue samples obtained at diagnosis (pre-treatment) 
and at progression (post-treatment). Red boxes indicate the presence of mutations 
detected by clinical routine sequencing procedures.  
 
Table 2. EGFR pathway mutations in parental and cetuximab resistant cell lines.  
Parental and correspondent cetuximab resistant derivatives of DiFi, LIM1215, HCA-46, 
NCIH508, OXCO-2 and CCK81 cell lines were analysed for KRAS, NRAS, BRAF, PIK3CA 
and EGFR mutations. Red boxes indicate the presence of the mutations (no specified 
alleles); in resistant cell lines, mutational analysis for EGFR exon 12 was performed by 
ddPCR and red boxes indicate which EGFR ectodomain alleles emerged. 
 
Figure 1. Structural analysis of EGFR extracellular domain mutants. A, General 
overview of the EGFR extracellular domain (sEGFR) bound to the antigen-binding 
fragment of cetuximab (Cetux) as crystallized by Li et al. Four subdomains comprise the 
sEGFR domain, domain III contains the six mutations. Mutation R451C occurs at the 
interface of contact with domain IV. B, Mutations I491M, S492R, S464L, G465R, K467T 
are located at the surface recognized by Cetux. A selection of residues located within 5 Å 
of the site of each mutation are shown. C, S464 (indicated in red, top left panel) is 
surrounded by Tyrosine residues (Y102 and Y104) which favor an H-bond network. G465 
(indicated in red, top right panel) lies in a highly hydrophobic groove formed by Y104, W54 
and W52, K467 (indicated in red, central left panel) defines a salt bridge with E58. I491 
(indicated in red, central right panel) is located in a hydrophobic environment formed by 
Q91, Y50 and Y104. S492 (indicated in red, bottom left panel) is located in an uncharged 
cavity formed by Y104, W94, P95, T98 and N91. R451(indicated in red, bottom right panel) 
is not located at the Cetux-sEGFR interface, but closer to the IV domain. Replacement by 
a Cysteine could form a new disulphide bond between domain III and IV. 
 
Figure 2. EGFR mutations differentially affect binding to cetuximab and 
panitumumab. A, NIH3T3 cells stably expressing wild type or the indicated EGFR 
mutations were incubated with cetuximab or panitumumab, and antibody binding was 
2 
 
analyzed by flow cytometry using a secondary antibody to human IgG conjugated with 
phycoerythrin (PE). NIH 3T3 cells expressing the empty vector were used as a negative 
control (Empty). Graphs show results of one representative experiment. B, The percentage 
of cells binding to the antibody are shown as relative values compared to EGFR wild-type 
(wt) cells (percentage of EGFR wt cells set to 1) and are mean values of two  independent 
experiments. While cetuximab binding was affected in cells expressing EGFR mutants, 
panitumumab was able to bind to cells expressing the S492R and K467T EGFR mutation. 
The R451C mutation had a moderate impact on binding to either cetuximab or 
panitumumab. 
 
 
Figure 3. Ligand-dependent activation of EGFR mutants in the presence of 
cetuximab and panitumumab. A-G, NIH 3T3 cells expressing WT EGFR or the indicated 
EGFR mutations were cultured in the presence of cetuximab (Ctx) or panitumumab (Pnm) 
for 2 h and stimulated with EGF (5 ng/ml) for 15’. Immunoblotting was performed using 
antibodies to the indicated proteins.  
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Supplementary table and figure legends 
 
Supplementary Table S1. Clinical characteristics of patients.  
Thirty-seven consecutive metastatic colorectal cancer patients that progressed to 
cetuximab after an initial response and that had good quality pre- and post- treatment 
tissue sample were included in this study. Chemotherapy schemes, FOLFOX, oxaliplatin 
85 mg m–2 on day 1, leucovorin 200 mg m–2 day 1, fluorouracil 400 mg m–2 bolus day 1, 
followed by a 2400 mg m–2 infusion during 22 hours, repeat every 2 weeks; FOLFIRI, 
irinotecan 180 mg m–2 on day 1, plus leucovorin 200 mg m–2, fluorouracil 400 mg m–2 
bolus day 1, followed by a 2400 mg m–2 infusion during 22 hours, repeat every 2 weeks; 
cetuximab 400 mg m–2 initial dose followed by 250 mg m–2 weekly thereafter; irinotecan 
180 mg m–2 every two weeks; *primary tumor localized in the colon with exact localization 
non specified. 
 
Supplementary Table S2. Validation of ddPCR probes. 
Validation of ddPCR probes on control mutant DNAs to detect EGFR variants previously 
identified in tumor biopsy or cell. 
 
Supplementary Table S3. Prevalence of EGFR mutations in resistant cell lines. 
  Prevalence of EGFR mutations in populations of resistant cells analyzed by ddPCR. 
 
Supplementary Figure S1. Nucleotide sequence of the EGFR gene in tumor 
specimen. 
Nucleotide sequence (electropherogram)  of the EGFR gene in tumor specimen from 
subject 31 and 35 at the time of progression to cetuximab revealing two different 
heterozygous mutations (K467T and R451C). 
 
Supplementary Figure S2. Comparison of parental and cetuximab resistant cell 
lines.  
Parental (in red) and cetuximab resistant (in black) DiFi, LIM1215, OXCO-2, HCA-46, 
NCIH508, and CCK81 cells were treated with increasing concentrations of cetuximab for 1 
week. Cell viability was measured by the adenosine triphosphate (ATP) assay. Data points 
represent means ± SD of three independent experiments.  
 
Supplementary Figure S3. Nucleotide sequence of the EGFR gene in cetuximab 
resistant cell lines. 
Nucleotide sequence (electropherogram) of the 3 new EGFR variants (S464L, G465R and 
I491M) found in cetuximab resistant cell lines.  
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Arena et al, Supplementary Figure S1. Nucleotide sequence of the EGFR gene in tumor specimen. 
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EGFR G465R  1393G>A  
EGFR I491M  1473A>G   
EGFR S464L  1391C>T   
Arena et al, Supplementary Figure S3. Nucleotide sequence of the EGFR gene in cetuximab resistant cell lines. 
Arena et al, Supplementary Table S1. Clinical characteristics of patients.  
Arena et al, Supplementary Table S2. Validation of ddPCR probes. 
EGFR p.R451C EGFR p.S464L EGFR p.G465R EGFR p.K467T EGFR p.I491M EGFR p.S492R 
EGFR 451 plasmid 100% 0,01% 0% 0% 0,02% 0% 
EGFR 464 plasmid 0% 100% 0% 0% 0,02% 0% 
EGFR 465 plasmid 0,01% 0% 100% 0% 0,01% 0% 
EGFR 467 plasmid 0,01% 0% 0,01% 100% 0,01% 0% 
EGFR 491 plasmid 0% 0,01% 0% 0% 100% 0% 
EGFR 492 plasmid 0% 0,02% 0,01% 0% 0% 100% 
Arena et al, Supplementary Table S3. Prevalence of EGFR mutations in resistant cell lines. 
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